Clinical Trial Update: A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating VLX-1005 versus placebo for suspected heparin-induced thrombocytopenia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heparin-induced Thrombocytopenia
• Immune Thrombocytopenia

Drugs mentioned

• VLX-1005

Snippet

Sponsor: Veralox Therapeutics | Conditions: Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia | Phase 2 | Status: TERMINATED